Stringent standards for generic products of highly complex biopharmaceuticals
Prof. Dr. Theo Dingermann
Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group, even in expert circles. This has all changed now, however, with the recent licensing of the first biosimilar antibody.